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Abstract 
 
Introduction. Comparative cross national (CNC) drug utilization studies are challenging. However, 
there can be concerns with the accuracy and robustness of the data collected with previous studies 
showing differences in utilisation rates between different databases. In addition, if utilisation rates vary 
appreciably between countries with no logical explanation. These studies have been carried out for 
the same class across countries. This has now been extended to compare utilisation rates between 
different databases among four high volume classes among administrative and commercial 
databases in one country (Lithuania) between 2004 and 2012 alongside health policies. Results: 
There were appreciable differences in the utilisation of PPIs (5 to 7 fold) and statins (2 to 6 fold) 
between the different databases with limited differences for the other two classes. This could be 
explained by restricted reimbursement for the PPIs and statins, with similar utilisation of renin-
angiotensin inhibitors in Lithuania between the databases and with Western European countries in the 
absence of prescribing restrictions. Low utilisation of anti-depressants in Lithuania versus Western 
European countries also explained by ongoing policies. Conclusion: Essential to always record the 
database content in CNC studies alongside health policies otherwise the findings could be 
misinterpreted. Joint reporting should become standard for future CNC studies. 
 
Introduction  
 
National and cross national comparative (CNC) drug utilization studies provide valuable information to 
policy makers to plan future measures to further enhance the quality and efficiency of their prescribing 
(1-5). Data sources for drug utilisation (DU) studies include administrative databases, patient 
registries, electronic health records and commercial databases (2, 6). However, CNC studies can be 
challenging as there can be differences in the data collected, e.g. whether dealing with reimbursed or 
total medicine utilisation, including also over-the-counter medicines, whether including all sectors or 
just inpatient or ambulatory care sectors and whether using similar units to measure and contrast 
utilisation and expenditure data. In addition, whether dealing with aggregated sales data or patient 
level data (2).  
 
There can also be concerns with the validity, reliability and robustness of the data. Concerns and 
issues relate firstly to structure of the databases used, i.e. the population included in the database. Is 
the data collected confined to a particular region or socio- demographic group that can make 
comparisons difficult. Secondly, whether there are factors that can appreciably affect utilization 
patterns which have not been discussed casting doubts on the figures (6, 7). For instance, 
atorvastatin was removed from the reimbursement list in Germany once generic simvastatin became 
available and patented angiotensin receptor blockers (ARBs) were removed from the reimbursement 
list in Denmark once generic losartan became available (8, 9). Both initiatives had a profound impact, 
e.g. utilization of patented atorvastatin fell to just 2% of overall statin utilization following this measure 
in Germany and losartan subsequently accounted for 93% of total ARB utilization in Denmark (8, 9).  
 
Different European countries have also introduced prescribing restrictions affecting subsequent 
utilization. Patented statins were restricted to second line in Norway and Finland, limiting their 
utilization in Finland to just 18.3% of total statin utilization, ARBs were restricted to second line after 
angiotensin converting enzyme inhibitors (ACEIs) in a number of European countries limiting their 
utilization and more recently patented ARBs were restricted to second line versus generics in Austria 
and Belgium following generic availability again significantly reducing their use (10-14).  
 
Prescribing restrictions and high co-payments for statins in Lithuania limited their reimbursed 
utilisation in 2007 to just 0.8 DIDs (Defined daily doses per 1000 inhabitants per day)  versus for 
instance 114.7 in Scotland with no such restrictions (6), despite the prevalence of coronary vascular 
disease higher in Lithuania than among Western European countries (15). Prescribing restrictions and 
high co-payments also limited the reimbursed utilisation of proton pump inhibitors (PPIs) in Lithuania 
in 2007 to just 2.3 DIDs in 2007 compared with for instance 76.9 in Scotland with no such restrictions 
(6).  Other authors have also shown that co-payments can appreciably affect subsequent utilization 
patterns (16-18).  
 
Thirdly, how often the data is checked for accuracy and reliability, i.e. robustness. Fourthly, how 
representational is the data for the population under consideration especially if a sample is being used 
and scaled up. These differences in data sources and regulations can lead to appreciable differences 
in utilisation rates in practice, e.g. differences up to 55% were seen in a pan-European study 
analysing statin utilisation rates between commercial and administrative databases (19).  
 
To date, studies comparing differences in utilisation rates between different databases have typically 
only included single classes apart from the study in France (6, 19, 20). This has now been extended 
to investigate utilisation differences between different databases in Lithuania among four high volume 
classes seen in Western European countries (6, 10, 19, 21-23), where there are differences in patient 
co-payment levels and other measures (Table 1). Medicines that are not reimbursed are not included 
in the Lithuanian National Health Insurance Fund (NHIF) database, with the robustness and accuracy 
of this database assured by the computerized dispensing records subject to frequent financial audits 
(24).  
 
 
  
Table 1 ± Prescribing regulations and restrictions across a number of classes in Lithuania 
 
Class Regulations including restrictions 
Antidepressants and 
anxiolytics 
x There is a 20% co-payment for reimbursed antidepressants 
x After 3 months, GPs are obliged to refer patients to a psychiatrist if they 
are not responding to the initial course of antidepressants (24) 
x Only two TCAs are currently reimbursed in Lithuania (amitryptiline and 
clomipramine). Otherwise there is 100% patient co-payment 
x There are no similar regulations for anxiolytics. As a consequence of this: 
o There is high utilisation of benzodiazepines in Lithuania at 40,5 
DIDs in 2012 with utilization of lorazepam at 20 DIDs in 2012  
o Lorazepam was the third most prescribed medicine (DDDs) in 
Lithuania in 2008 and the fourth most prescribed medicine in 
2009 (24). 
Proton pump 
inhibitors (PPIs) 
x PPIs have a 50% co-payment for reimbursement, with reimbursement is 
currently restricted to patients with reflux oesophagitis, duodenal ulcers, or 
for Helicobacter pylori eradication (6, 24) 
x Until 2006 omeprazole, rabeprazole and esomeprazole were reimbursed.  
x From 2006, only omeprazole was reimbursed in view of the higher 
requested prices of essentially similar PPIs. Other PPIs 100% co-payment 
 
Renin-angiotensin 
inhibitors 
x There is a 20% co-payment for reimbursed Angiotensin Converting 
Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) 
x There are currently no prescribing restrictions for ACEIs in patients with 
hypertension 
x There are currently prescribing restrictions for originator/ patented ARBs, 
i.e. active substances without generic analogues 
Statins x There is currently a 20% co-payment for reimbursed statins 
x Statins were only reimbursed for secondary prevention up to 2008, and up 
to 2006 only for the first 6 months, enforced through a bar coding system 
in pharmacies 
x In addition up to 2006, statins could only be prescribed by cardiologists for 
reimbursement 
x Since 2006, the first prescription must still be issued by a cardiologist 
although GPs are subsequently allowed to continue prescribing, which is 
enforced through an active gatekeeper system in Lithuania (6, 24, 25).  
x The prescribing restrictions were lifted for generic statins at the end of 
May 2009 (6, 24, 26), with family physicians now allowed to prescribe 
generic statins. 
NB: DDDs = Defined daily doses; DIDs = DDDs per one thousand inhabitants per day; TCAs = Tricyclic 
antidepressants 
 
Methods 
 
Four drug classes were chosen for comparisons between available databases in Lithuania. These 
were the PPIs, statins, renin-angiotensin inhibitor medicines, i.e. ACEIs and ARBs, as well as 
selective serotonin reuptake inhibitors (SSRIs) and newer antidepressants ± venlafaxine, mirtazapine, 
reboxetine and duloxetine. IMS Baltic provided the IMS data, with all figures converted to DIDs for 
comparison. 
 
Results 
 
x PPIs 
 
Total PPI utilisation in the IMS database increased from 4.9 DIDs in 2004 to 21.2 DIDs in 2012, 
representing an average annualised percentage increase of 41.5% (Table 2). Reimbursed PPI 
utilisation also increased, with a similar average annual percentage change. 
 
  
Table 2 ± Utilisation of PPIs 2004 to 2012 among administrative (NHIF) and IMS databases in DIDs 
 
 Year/ database 2004 2005 2006 2007 2008 2009 2010 2011 2012 
IMS (Total)  4.9 7.0 10.4 13.8 18.7 17.6 17.9 20,0 21.2 
NHIF reimbursed 0.7 1.4 2.0 2.3 2.9 2.8 
 
2.9 
 
2.9 
 
3.0 
% reimbursed vs. IMS 14.5 19.6 19.0 16.5 15.6 15.9 
 
16.3 
 
14.8 
 
14.3 
 
There was a 5 to 7 fold difference (Table 2) between the utilisation of PPIs documented in IMS 
(commercial) versus NHIF (administrative) database, with utilisation in the NHIF database varying 
between 14.3 to 19.6% of IMS figures. 
 
x Statins  
 
Statin utilisation increased by just over 5 fold from 2.4 DIDs in 2004 to 12.9 DIDs in 2012 in the IMS 
database, with a greater rate of increase in the NHIF database (Table 3). 
 
Table 3 ± Utilisation of statins 2004 to 2012 among administrative (NHIF) and IMS databases in DIDs 
 
 Year/ database 2004 2005 2006 2007 2008 2009 2010 2011 2012 
IMS total 2.4 2.3 3.1 4.5 7.1 7.7 8.3 10.6 12.9 
NHIF reimbursed  0.6 0.6 0.7 0.8 1.1 1.8 
 
3.5 
 
5.3 
 
7.3 
% of NHIF database  vs. 
IMS 23.2 27.4 21.3 17.5 15.1 23.5 
 
42.2 
 
50.2 
 
56.8 
 
Utilisation patterns for the statins were similar between those documented in the Soft Dent database 
(another commercial database for recording drug utilisation patters in Lithuania) between 2005 and 
2007 and the data from IMS (Table 3) at 2.7 to 4.4 DIDs (27). 
 
Utilisation patterns in the NHIF (administrative) database were again lower compared with IMS 
database findings. Overall, utilisation of statins in the NHIF database ranged between 15.1% to 56.8% 
of total IMS utilisation during the study period, with differences reducing once prescribing restrictions 
were lifted for generic statins (May 2009 onwards). 
 
x ACEIs and ARBs 
 
Total utilisation of single ACEIs and ARBs in both database grew steadily during the study period 
(Table 4) with utilisation similar between the databases with reimbursed utilisation rates varying 
between 75.6% to 89.5% of total IMS utilisation (Table 4) between 2004 and 2012. 
 
Table 4 ± Utilisation of single ACEIs and ARBs 2004 to 2012 among administrative (NHIF) and IMS 
databases in DIDs 
 
 Year/ database 2004 2005 2006 2007 2008 2009 2010 2011 2012 
IMS total  99.7 100.8 117.3 131.4 147.5 147.3 150,8 152,2 155,3 
NHIF reimbursed 75.4 83.6 97.2 111.3 128.2 131.8 
 
134.2 
 
130.8 
 
131.5 
% of reimbursed vs. IMS 
 
75.6 83.0 82.9 84.7 86.9 89.5 
 
89.0 
 
86.0 
 
84.6 
          
 
The annual increase in utilisation of ACEIs and ARBs was similar between at 9.3% per year in the 
NHIF and 7% in the IMS database. 
 
  
x Selected antidepressants  
 
The utilisation of selected antidepressants grew steadily in both databases (Table 5), with limited 
differences between them, i.e. reimbursed utilisation (NHIF) rates varying between 70.7% to 88.7% of 
IMS utilisation (Table 5).  
 
Table 5 ± Utilisation of selected antidepressants 2004 to 2012 among administrative (NHIF) and IMS 
databases in DIDs 
 
 Year/ database 2004 2005 2006 2007 2008 2009 2010 2011 2012 
IMS total  7.7 8.1 10.0 11.7 13.4 13.7 16.3 18.2 19.2 
NHIF reimbursed  5.4 6.5 7.9 8.9 11.0 12.1 
 
14.5 
 
15.3 
 
16.3 
% of reimbursed  vs. 
IMS 70.7 79.9 78.8 75.5 82.7 88.4 
 
88.7 
 
83.8 
 
83.5 
 
 
Discussion  
 
There can be appreciable differences between utilisation rates in IMS (total) versus reimbursed 
databases in Lithuania; however, this is not always the case (Tables 2 to 5). Where these occur, e.g. 
for the PPIs and statins, these can be explained by the specific policies in Lithuania (Table 1). 
Interestingly, the differences seen for the statins between the various databases (Table 3) were much 
greater than seen in previous studies across Europe (1, 19), which shows the value of additional 
research.  Not surprisingly, there was convergence in utilisation rates between the databases once 
the reimbursement restrictions were lifted for the statins (Tables 1 and 2) in view of the prevalence of 
CHD in Lithuania (15). 
 
The lack of any major difference in the utilisation of the renin-angiotensin inhibitors between the 
different databases with no prescribing restrictions in Lithuania (Tables 1 and 4), and similar utilisation 
patterns to Western European countries in 2007 (10, 26), further demonstrates that prescribing 
restrictions can appreciably influence subsequent utilisation rates (21, 28). As a result, demonstrating 
the need to accurately document ongoing reforms in any CNC study. The increase in statin utilisation 
following the removal of prescribing restrictions (Table 3) further supports this. 
 
Similar utilisation rates for antidepressants in Lithuania between the databases is not unexpected 
(Table 5).  However, the lower utilization at 10.45 DIDs in 2007 in Lithuania versus 40.0 in Austria, 
49.4 in Portugal, 61.9 in Scotland, 59.5 in Spain (Catalonia) and 57.3 in Sweden [BBG unpublished 
data] can potentially be explained by general practitioners being required to transfer patients to a 
psychiatrist if there is no clinical improvement, which is still associated with a stigma by some (Table 
1) (24, 29). This appears to be compensated by high use of benzodiazepines in Lithuania (Table 1), 
endorsing the findings of currently low utilisation rates for antidepressants in Lithuania especially 
since there is also limited utilisation of tricyclic antidepressants at approximately 11% of total 
reimbursed prescriptions for depression in Lithuania during recent years (KG ± unpublished data). 
 
These combined findings means it is essential for researchers to always accurately record the content 
of each database, as well as any concomitant health policies and other activities that may influence 
utilisation patterns. Otherwise, there could be suspicion with findings that show considerably lower 
utilisation rates in one database compared with another as well as one country versus another.  
 
These findings also have implications for conducting and analysing budget impact analyses and cost-
effectiveness analyses, where for instance the database used could make a substantial difference to 
any budget impact calculations. This is a key learning point for researchers and others when 
undertaking single and CNC drug utilisation studies. 
 
In conclusion, these findings demonstrate it is essential for drug utilisation and other researchers to 
always fully document health policy initiatives alongside the content of each database to enhance the 
interpretation of their findings and their implications. Otherwise, there may be a tendency for 
researchers and healthcare professionals to dismiss very low or very high utilisation rates as not 
being valid if these cannot be explained by epidemiological factors alone. There may also be 
considerable differences in budget impact calculations depending which database is used, as well as 
potentially cost-effectiveness analyses, necessitating again the need for drug utilisation researchers 
to accurately record the database characteristics used in any analysis.   
 
Consequently, we believe this joint reporting should become standard for all future CNC drug 
utilisation studies. As a result, increasing the need for drug utilisation researchers and health authority 
personnel to work closely together in the future.  
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